A retrospective survey of quality of reporting on randomized controlled trials of metformin for polycystic ovary syndrome

Trials

Minyan Li¹  Chun Zhang¹  Jian Liu¹  Baoying Chen¹ 

[1] Department of Traditional Chinese Medicine, The First People’s Hospital of Shunde, Foshan, PR China

关键词: The CONSORT Statement;    Polycystic ovary syndrome;    Randomized controlled trials;    Quality of reporting;    Metformin;   

Others  :  806863
DOI  :  10.1186/1745-6215-15-128

 received in 2013-06-20, accepted in 2014-04-03,  发布年份 2014

【 摘 要 】

Background

From previous reviews, there still have been controversies over the effect of metformin (MET) on reproductive function in PCOS patients. The reasons for the inconsistent findings especially lie in the transparency and accuracy of randomized controlled trials (RCTs) reports. However, we could find no data about the quality of RCTs reporting in MET for PCOS. Thus, a retrospective survey related to the quality of reporting in MET for PCOS was conducted.

Methods

A retrospective survey was conducted by two investigators. Two investigators assessed the quality of overall reporting and key methodological factors reporting using items from the CONSORT 2010 statement.

Results

A total of 39 RCTs were included in full text. The median overall quality score was 9, with a minimum of 2 and a maximum of 13. Good or general reporting existed in 11 items with positive rate of more than or equal to 50%. The median score of key methodological items was 4 with a minimum of 0 and a maximum of 5. Randomization, allocation concealment, blinding, baseline characteristics and intention-to-treat (ITT) analysis were reported in 26 (67%), 19 (49%), 20 (51%), 38 (97%) and 17 (44%) of the 39 RCTs, respectively. After adjustment, the mean overall score increased by about 1.71 for manuscripts with funding source (95% CI, 0.18 to 3.24), while it increased by about 3.51 for manuscripts published in one year increment (95% CI, 1.82 to 5.19). There was a relatively close, significant correlation (r = 0.589, P < 0.001) between the score of overall reporting quality and year of publication.

Conclusion

Although the overall reporting quality of RCTs in MET for PCOS has improved over time, reporting of key methodological items remains poor. Reporting of RCTs on MET for PCOS should keep up with the standards of the CONSORT statement.

【 授权许可】

   
2014 Chen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Kahn JA, Gordon CM: Polycystic ovary syndrome. Adolesc Med 1999, 10:321-336.
• [2]Carmina E, Lobo RA: Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999, 84:1897-1899.
• [3]Pritts EA: Treatment of the infertile patient with polycystic ovarian syndrome. Obstet Gynecol Surv 2002, 57:587-597.
• [4]Diamanti-Kandarakis E: Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med 2008, 10:e3.
• [5]Siassakos D, Wardle P: Polycystic ovary syndrome and pregnancy outcome: red herring or red flag? BJOG 2007, 114:922-932.
• [6]Costello MF, Eden JA: A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. Fertil Steril 2003, 79:1-13.
• [7]Lord JM, Flight IH, Norman RJ: Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003, 327:951-953.
• [8]Kashyap S, Wells GA, Rosenwaks Z: Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. Hum Reprod 2004, 19:2474-2483.
• [9]Siebert TI, Kruger TF, Steyn DW, Nosarka S: Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review. Fertil Steril 2006, 86:1432-1437.
• [10]Moll E, van der Veen F, van Wely M: The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Update 2007, 13:527-537.
• [11]Creanga AA, Bradley HM, McCormick C, Witkop CT: Use of metformin in polycystic ovary syndrome - A meta-analysis. Obstet Gynecol 2008, 111:959-968.
• [12]Palomba S, Pasquali R, Orio F, Nestler JE: Clomiphene citrate, metformin or both as first-step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head-to-head randomized controlled studies and meta-analysis. Clin Endocrinol 2009, 70:311-321.
• [13]Sun X, Zhang D, Zhang W: Effect of metformin on ovulation and reproductive outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. Arch Gynecol Obstet 2013, 288:423-430.
• [14]Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Giudice LC, Leppert PC, Myers ER: Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007, 356:551-566.
• [15]Zain MM, Jamaluddin R, Ibrahim A, Norman RJ: Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial. Fertil Steril 2009, 91:514-521.
• [16]Dunaif A: Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome - a reappraisal. Nat Clin Pract Endocrinol Metab 2008, 4:272-283.
• [17]Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH: Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 2012., 5CD003053
• [18]Lu L, Zeng J, Chen Y: Quality of reporting in randomized controlled trials conducted in China on the treatment of cancer pain. Expert Rev Anticancer Ther 2011, 11:871-877.
• [19]Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG, Consort: CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg 2012, 10:28-55.
• [20]Toulmonde M, Bellera C, Mathoulin-Pelissier S, Debled M, Bui B, Italiano A: Quality of randomized controlled trials reporting in the treatment of sarcomas. J Clin Oncol 2011, 29:1204-1209.
• [21]Diallo S, Cour F, Josephson A, Vidart A, Botto H, Lebret T, Bonan B: Evaluating single-incision slings in female stress urinary incontinence: the usefulness of the CONSORT statement criteria. Urology 2012, 80:535-541.
• [22]Rios LP, Odueyungbo A, Moitri MO, Rahman MO, Thabane L: Quality of reporting of randomized controlled trials in general endocrinology literature. J Clin Endocrinol Metab 2008, 93:3810-3816.
• [23]Lai R, Chu R, Fraumeni M, Thabane L: Quality of randomized controlled trials reporting in the primary treatment of brain tumors. J Clin Oncol 2006, 24:1136-1144.
• [24]Hollis S, Campbell F: What is meant by intention to treat analysis? Survey of published randomised controlled trials. Br Med J 1999, 319:670-674.
• [25]Gluud LL, Thorlund K, Gluud C, Woods L, Harris R, Sterne JAC: Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2008, 149:596-596.
• [26]Montori VM, Bhandari M, Devereaux PJ, Manns BJ, Ghali WA, Guyatt GH: In the dark - The reporting of blinding status in randomized controlled trials. J Clin Epidemiol 2002, 55:787-790.
• [27]Dias S, McNamee R, Vail A: Evidence of improving quality of reporting of randomized controlled trials in subfertility. Hum Reprod 2006, 21:2617-2627.
• [28]Farrokhyar F, Chu R, Whitlock R, Thabane L: A systematic review of the quality of publications reporting coronary artery bypass grafting trials. Can J Surg 2007, 50:266-277.
• [29]Scales CD Jr, Norris RD, Keitz SA, Peterson BL, Preminger GM, Vieweg J, Dahm P: A critical assessment of the quality of reporting of randomized, controlled trials in the urology literature. J Urol 2007, 177:1090-1094.
• [30]Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF: Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996, 276:637-639.
• [31]Prady SL, Richmond SJ, Morton VM, Macpherson H: A systematic evaluation of the impact of STRICTA and CONSORT recommendations on quality of reporting for acupuncture trials. PLoS One 2008, 3:e1577.
• [32]Cobo E, Cortes J, Ribera JM, Cardellach F, Selva-O’Callaghan A, Kostov B, Garcia L, Cirugeda L, Altman DG, Gonzalez JA, Sanchez JA, Miras F, Urrutia A, Fonollosa V, Rey-Joly C, Vilardell M: Effect of using reporting guidelines during peer review on quality of final manuscripts submitted to a biomedical journal: masked randomised trial. Br Med J 2011, 22:343.